July 27, 2012
Eli Lilly Japan announced on July 24 the results of its post-marketing pharmacological study that investigated the impact of the combination of the osteoporosis treatment Forteo (teriparatide) coadministered with an activated vitamin D 3 preparation on serum calcium (Ca) levels...read more